Suppr超能文献

用β/γ 二联体替代α-残基三联体,获得具有独特信号特征的激素类似物。

Hormone Analogues with Unique Signaling Profiles from Replacement of α-Residue Triads with β/γ Diads.

机构信息

Department of Chemistry, University of Wisconsin, 1101 University Avenue, Madison, Wisconsin 53706, United States.

Department of Chemistry, The Scripps Research Institute, La Jolla, California 92037, United States.

出版信息

J Am Chem Soc. 2023 Sep 20;145(37):20539-20550. doi: 10.1021/jacs.3c06703. Epub 2023 Sep 11.

Abstract

We have applied an underexplored backbone modification strategy to generate new analogues of peptides that activate two clinically important class B1 G protein-coupled receptors (GPCRs). Most peptide modification strategies involve changing side chains or, less commonly, changing the configuration at side chain-bearing carbons (i.e., l residues replaced by d residues). In contrast, backbone modifications alter the number of backbone atoms and the identities of backbone atoms relative to a poly-α-amino acid backbone. Starting from the peptide agonists PTH(1-34) (the first 34 residues of the parathyroid hormone, used clinically as the drug teriparatide) and glucagon-like peptide-1 (7-36) (GLP-1(7-36)), we replaced native α-residue triads with a diad composed of a β-amino acid residue and a γ-amino acid residue. The β/γ diad retains the number of backbone atoms in the ααα triad. Because the β and γ residue each bear a single side chain, we implemented ααα→βγ replacements at sites that contained a Gly residue (i.e., at α-residue triads that presented only two side chains). All seven of the α/β/γ-peptides derived from PTH(1-34) or GLP-1(7-36) bind to the cognate receptor (the PTHR1 or the GLP-1R), but they vary considerably in their activity profiles. Outcomes include functional mimicry of the all-α agonist, receptor-selective agonist activity, biased agonism, or strong binding with weak activation, which could lead to antagonist development. Collectively, these findings demonstrate that ααα→βγ replacements, which are easily implemented via solid-phase synthesis, can generate peptide hormone analogues that display unique and potentially useful signaling behavior.

摘要

我们应用了一种尚未充分探索的骨架修饰策略,来生成能激活两种临床上重要的 B1 类 G 蛋白偶联受体(GPCR)的新型肽类似物。大多数肽修饰策略涉及改变侧链,或者较少见地,改变带有侧链的碳原子的构型(即,l 残基被 d 残基取代)。相比之下,骨架修饰会改变骨架原子的数量和相对于聚-α-氨基酸骨架的骨架原子的身份。从肽激动剂 PTH(1-34)(甲状旁腺激素的前 34 个残基,临床上用作药物特立帕肽)和胰高血糖素样肽-1(7-36)(GLP-1(7-36))开始,我们用由β-氨基酸残基和γ-氨基酸残基组成的二联体取代了天然的α-残基三联体。β/γ二联体保留了ααα三联体中的骨架原子数量。由于β和γ残基各带有一个侧链,因此我们在含有甘氨酸残基的位点(即,仅带有两条侧链的α-残基三联体)实施了ααα→βγ替换。从 PTH(1-34)或 GLP-1(7-36)衍生的 7 种α/β/γ-肽都与相应的受体(PTHR1 或 GLP-1R)结合,但它们的活性谱差异很大。结果包括对全-α激动剂的功能模拟、受体选择性激动剂活性、偏激动剂作用或强结合弱激活,这可能导致拮抗剂的开发。总的来说,这些发现表明,通过固相合成很容易实现的ααα→βγ替换可以生成具有独特且可能有用的信号转导行为的肽激素类似物。

相似文献

1
Hormone Analogues with Unique Signaling Profiles from Replacement of α-Residue Triads with β/γ Diads.
J Am Chem Soc. 2023 Sep 20;145(37):20539-20550. doi: 10.1021/jacs.3c06703. Epub 2023 Sep 11.
2
Impact of Substitution Registry on the Receptor-Activation Profiles of Backbone-Modified Glucagon-like Peptide-1 Analogues.
Chembiochem. 2019 Nov 18;20(22):2834-2840. doi: 10.1002/cbic.201900300. Epub 2019 Sep 20.
3
Characterization of signal bias at the GLP-1 receptor induced by backbone modification of GLP-1.
Biochem Pharmacol. 2017 Jul 15;136:99-108. doi: 10.1016/j.bcp.2017.03.018. Epub 2017 Mar 29.
4
Backbone Modification of a Parathyroid Hormone Receptor-1 Antagonist/Inverse Agonist.
ACS Chem Biol. 2016 Oct 21;11(10):2752-2762. doi: 10.1021/acschembio.6b00404. Epub 2016 Aug 17.
5
β-Arrestin-Biased Agonists of the GLP-1 Receptor from β-Amino Acid Residue Incorporation into GLP-1 Analogues.
J Am Chem Soc. 2016 Nov 16;138(45):14970-14979. doi: 10.1021/jacs.6b08323. Epub 2016 Nov 4.
6
Receptor selectivity from minimal backbone modification of a polypeptide agonist.
Proc Natl Acad Sci U S A. 2018 Dec 4;115(49):12383-12388. doi: 10.1073/pnas.1815294115. Epub 2018 Nov 15.
7
Effects of Replacing a Central Glycine Residue in GLP-1 on Receptor Affinity and Signaling Profile.
Chembiochem. 2023 Nov 2;24(21):e202300504. doi: 10.1002/cbic.202300504. Epub 2023 Sep 13.
8
Differential Responses of the GLP-1 and GLP-2 Receptors to N-Terminal Modification of a Dual Agonist.
J Am Chem Soc. 2023 Jun 7;145(22):12105-12114. doi: 10.1021/jacs.3c01628. Epub 2023 May 26.
9
Development of Potent, Protease-Resistant Agonists of the Parathyroid Hormone Receptor with Broad β Residue Distribution.
J Med Chem. 2017 Nov 9;60(21):8816-8833. doi: 10.1021/acs.jmedchem.7b00876. Epub 2017 Oct 24.
10
Recognition of Class II MHC Peptide Ligands That Contain β-Amino Acids.
J Immunol. 2019 Sep 15;203(6):1619-1628. doi: 10.4049/jimmunol.1900536. Epub 2019 Aug 7.

本文引用的文献

1
Differential Responses of the GLP-1 and GLP-2 Receptors to N-Terminal Modification of a Dual Agonist.
J Am Chem Soc. 2023 Jun 7;145(22):12105-12114. doi: 10.1021/jacs.3c01628. Epub 2023 May 26.
2
Molecular insights into peptide agonist engagement with the PTH receptor.
Structure. 2023 Jun 1;31(6):668-676.e5. doi: 10.1016/j.str.2023.04.002. Epub 2023 May 5.
3
/Sulfono--AA peptide hybrids agonist of GLP-1R with prolonged action both and .
Acta Pharm Sin B. 2023 Apr;13(4):1648-1659. doi: 10.1016/j.apsb.2022.10.014. Epub 2022 Oct 21.
4
Altered signaling at the PTH receptor via modified agonist contacts with the extracellular domain provides a path to prolonged agonism in vivo.
Proc Natl Acad Sci U S A. 2022 Nov 29;119(48):e2212736119. doi: 10.1073/pnas.2212736119. Epub 2022 Nov 21.
5
Kinetic and Thermodynamic Insights into Agonist Interactions with the Parathyroid Hormone Receptor-1 from a New NanoBRET Assay.
ACS Chem Biol. 2022 Nov 18;17(11):3148-3158. doi: 10.1021/acschembio.2c00595. Epub 2022 Oct 25.
6
Endogenous ligand recognition and structural transition of a human PTH receptor.
Mol Cell. 2022 Sep 15;82(18):3468-3483.e5. doi: 10.1016/j.molcel.2022.07.003. Epub 2022 Aug 5.
7
Structural perspective of class B1 GPCR signaling.
Trends Pharmacol Sci. 2022 Apr;43(4):321-334. doi: 10.1016/j.tips.2022.01.002. Epub 2022 Jan 22.
8
Dynamics of GLP-1R peptide agonist engagement are correlated with kinetics of G protein activation.
Nat Commun. 2022 Jan 10;13(1):92. doi: 10.1038/s41467-021-27760-0.
9
Exploration of α/β/γ-peptidomimetics design for BH3 helical domains.
Chem Commun (Camb). 2022 Jan 20;58(7):945-948. doi: 10.1039/d1cc05758h.
10
Structural and functional diversity among agonist-bound states of the GLP-1 receptor.
Nat Chem Biol. 2022 Mar;18(3):256-263. doi: 10.1038/s41589-021-00945-w. Epub 2021 Dec 22.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验